How Quantifying Amyloid Scans Transforms Dementia Care

Diagnosing Alzheimer’s disease in clinical practice remains a significant challenge for neurologists and nuclear medicine specialists in India. While visual reading of amyloid scans is the standard method, it often suffers from inter-reader variability. Consequently, a landmark multicentre study shows that integrating quantitative amyloid PET into clinical workflows dramatically enhances reader confidence and visual interpretation accuracy. This advance is particularly crucial as newer amyloid-targeting therapies become available in clinical practice.

Why Quantitative Amyloid PET Matters in Clinical Practice

Traditionally, clinicians classify amyloid positron emission tomography (PET) scans using binary visual assessments. However, this visual approach is limited by subjective interpretations and tracer differences. Therefore, researchers conducted a retrospective multicentre study involving 950 patients who underwent scans between 2015 and 2022. The patients received F-18 florbetaben, flutemetamol, or florapronol. Initially, readers evaluated the scans by visual assessment alone. Afterwards, they re-evaluated them using quantitative standardized uptake value ratios and Centiloid analysis. This combined approach sought to measure real-world clinical utility.

Key Findings and Clinical Benefits

Crucially, the results demonstrated that quantitative software vastly improves diagnostic performance. Specifically, high-confidence interpretations rose from 76.3% with visual reading alone to 83.7% with quantitative assistance. Furthermore, inter-reader agreement improved from moderate to substantial, with the Fleiss’ kappa score rising from 0.58 to 0.72. Additionally, overall agreement with expert consensus increased from 88.5% to 94.2%. Most importantly, Centiloid scaling resolved 82% of interpretive ambiguities in borderline or discordant cases. Thus, adding quantitative tools provides clear clinical direction where subjective visual assessment fails.

Frequently Asked Questions

Q1: How does quantitative analysis help in interpreting amyloid PET scans?

It provides standardized metrics like Centiloid values and standardized uptake value ratios. Consequently, this objective data increases diagnostic confidence, reduces subjectivity, and resolves up to 82% of borderline or discordant cases.

Q2: Does quantitative analysis reduce variability between different readers?

Yes. Transitioning to adjunctive quantitative analysis significantly reduces inter-reader variability. Specifically, in this study, the agreement metric between readers rose from a moderate 0.58 to a substantial 0.72.

Q3: What tracers were evaluated in this multicentre study?

The study retrospectively evaluated scans using three common fluorine-18 labeled tracers. Specifically, the research included florbetaben, flutemetamol, and florapronol.

References

1. Ha S et al. Impact of adjunctive quantitative analysis on visual interpretation of amyloid PET: a multiple tracer, multicentre study. Eur Radiol. 2026 Jun 18. doi: 10.1007/s00330-026-12687-1. PMID: 42310039.
2. Khalafi M et al. Concordance between Centiloid Quantification and Visual Interpretation of Amyloid PET Scans across the Alzheimer Disease Continuum. AJNR Am J Neuroradiol. 2025 Sep 2;46(9):1884-1892. doi: 10.3174/ajnr.A8743. PMID: 39223123.
3. Collij LE et al. Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study. J Nucl Med. 2025 Jan 3;66(1):110-116. doi: 10.2967/jnumed.124.268119.